Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

Table 1

Patient characteristics

No of patients	28
Male	16	57%
Female	12	43%
Median age, y, (range)	58	(32–81)
Performance status
0-1	22	79%
2	6	21%
Primary tumor
Pancreas	7	25%
Esophagus	3	11%
Gastric	3	11%
Colon	4	14%
CUP (unknown primary)	6	21%
Other sites		18%
Rectum	1
Prostate	1
Lung	1
Kidney	1
Chromogranin A immunohistochemistry
Strongly positive	19
Weak	6
Negative	3
Synaptophysin immunohistochemistry
Strongly positive	28
Negative	0
Somatostatin receptor scintigraphy
Strongly positive (>liver uptake)	8
Weakly positive (≤liver uptake)	3
Negative	10
Not done	7
Ki-67
Median, %, (range)	50	(20–100)
≥50%	17
<50%	11
Site of metastases
Liver	24
Lymph nodes	22
Lung	4
Bone	3
Pelvic, brain, renal, breast, skin,  peritoneal	10
No. of metastatic sites
1	4
2	13
≥3	11